VEGFC and neoplasm: In tumor budding regions, which reflect the spreading capacity of tumor cells, the percentage distribution of cases with positive VEGFR-2 ligand immunoreactivity was similar to the tumor center, namely 71 % for VEGF-C and 55 % for VEGF-D (Table 1).